Greenberg Traurig and Goodwin Procter are advising on the $2.4 billion sale of American cancer drugmaker Deciphera to Japanese company ONO Pharmaceutical.
Under the terms of the agreement, ONO will acquire all outstanding shares of Deciphera, a 2003-founded biopharmaceutical company focused on developing cancer drugs, for $25.60 per share in cash.
